Evaluating a Multilevel Communication Campaign to Increase HIV Vaccine Trial Enrollment

评估多层次沟通活动以增加艾滋病毒疫苗试验注册人数

• 批准号: 10625227
• 负责人: Michele Peake Andrasik
• 金额: $ 65.12万
• 依托单位: FRED HUTCHINSON CANCER CENTER
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-05-19 至 2028-02-29
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10625227
• 关键词: Address; Advertising; Affect; Awareness; Behavioral; Black, Indigenous, People of Color; COVID-19; COVID-19 Prevention Network; COVID-19 pandemic; COVID-19 vaccine; Classification; Collaborations; Communication; Communities; Data; Development; Dissemination and Implementation; Educational Curriculum; Effectiveness; Electronic Mail; Enrollment; Facebook; Focus Groups; Funding; Future; Goals; Government; HIV; HIV Vaccine Trials Network; HIV vaccine; Health; Health Services; Instagram; International; Interruption; Knowledge; Lesbian Gay Bisexual Transgender Queer; Longterm Follow-up; Marketing; Measures; Media Campaign; Medical Research; Misinformation; Modeling; Outcome; Participant; Patient Recruitments; Performance; Phase; Phase III Clinical Trials; Population Heterogeneity; Positioning Attribute; Preventive; Protocols documentation; Published Comment; Registries; Research; Research Personnel; Series; Surveys; Taxonomy; Testing; Time; Training; Trust; Twitter; United States; Vaccine Clinical Trial; Vaccines; Visit; Work; clinical research site; clinical training; combat; community based participatory research; community engagement; community partnership; design; early phase trial; efficacy testing; eligible participant; equity, diversity, and inclusion; evidence base; experience; forging; health communication; implementation research; improved; innovation; marginalized community; multidisciplinary; outreach; participant enrollment; primary outcome; programs; recruit; seropositive; social media; social stigma; trend analysis; trial enrollment; trustworthiness; vaccine hesitancy; vaccine trial; virtual; web site

Project Summary/Abstract The HIV Vaccine Trials Network (HVTN) has experienced significant challenges recruiting participants in early-stage HIV vaccine clinical trials. Formidable barriers to participation in HVTN preventive HIV early phase trials, including lack of HIV public urgency, numerous study visits, long-term follow-up, vaccine induced seropositivity and HIV stigma, have resulted in significant challenges enrolling participants into these trials. We will co-refine an existing media campaign, develop, test and evaluate a multilevel communication strategy to address some of these crucial concerns and strengthen our reputation of trustworthiness in marginalized communities disproportionately affected by HIV to increase their enrollment into early-stage HIV vaccine trials. Over the next 7 years, the HVTN will focus on the early phase trial program to move the field forward and to identify products efficiently and effectively for later efficacy testing. This will require the development and deployment of evidence-based strategies to combat misinformation and to strengthen community engagement. Our team and the clinical research sites in our Network have forged longstanding community partnerships with diverse stakeholders. During our phase 3 clinical trials for the US government-funded COVID-19 vaccine clinical trials we developed new strategies to supplement our community engagement program: (1) a consumer-driven marketing and advertising campaign; (2) virtual town halls and listening sessions; and (3) the use of expert panels to review protocols and provide guidance and direction. We will build on this work to inform our HIV strategy. We assembled an experienced team of diverse researchers to accomplish the following aims: 1) Identify components of an initial media campaign that impact HIV vaccine trial registration and develop a multilevel communication strategy; 2) Evaluate the impact of the multilevel communication strategy on Phase I HIV vaccine trial registration; and 3) Determine if the multilevel communication strategy generates public engagement with vaccines and vaccine trials. This project will be the first large-scale communication study conducted in the United States to improve community awareness of and engagement with HIV vaccine trial research. It will assess misinformation and engagement with this strategy to inform current and future HIV vaccine trials recruitment and is expected to have a positive health impact by establishing robust strategies to improve diversity, equity, and inclusion in Phase 1 preventive HIV vaccine trials.

项目总结/文摘